Key Takeaways:
- Agilon Health (AGL, Financial) shares experience a remarkable 30% rise following an upgrade by Bernstein.
- Despite recent volatility, the stock has achieved a 176% increase year-to-date.
- Analysts predict potential significant upside based on GF Value estimates.
Agilon Health (AGL) has captured investor attention with its shares soaring nearly 30% due to Bernstein's recent upgrade from Hold to Buy, complemented by a new price target of $8.50. The upgrade stems from encouraging new data supporting Agilon Health's strategic turnaround and robust financial fundamentals. This movement contributes to the company's impressive 176% gain so far this year, despite experiencing volatility.
Wall Street Analysts Forecast
Currently, 15 analysts have set a one-year price target for Agilon Health Inc (AGL, Financial). The average target is $3.40, with estimates ranging from a high of $6.00 to a low of $2.00. This average target suggests a potential downside of 36.57% from Agilon's current price of $5.36. For more in-depth estimate information, visit the Agilon Health Inc (AGL) Forecast page.
Evaluating recommendations from 22 brokerage firms, Agilon Health Inc (AGL, Financial) maintains an average brokerage recommendation of 3.0, classified as "Hold." This recommendation scale spans from 1 (Strong Buy) to 5 (Sell), providing a clear gauge of market sentiment.
GuruFocus GF Value Estimate
In an optimistic outlook, GuruFocus estimates the GF Value for Agilon Health Inc (AGL, Financial) in one year to be $36.86. This indicates a striking potential upside of 587.69% from the current trading price of $5.36. The GF Value reflects GuruFocus' assessment of the stock's fair market value, derived from historical price multiples and expectations for future business performance. For broader insights, explore additional data on the Agilon Health Inc (AGL) Summary page.
